Agios Pharmaceuticals (AGIO) News Today $41.96 -0.73 (-1.71%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell DiseaseDecember 18 at 7:00 AM | globenewswire.comQ1 EPS Forecast for Agios Pharmaceuticals Lowered by AnalystDecember 17 at 1:55 AM | americanbankingnews.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock Price Up 5.2% - Should You Buy?Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Up 5.2% - Here's WhyDecember 16 at 12:56 PM | marketbeat.comState Street Corp Acquires 216,484 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)State Street Corp boosted its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 10.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,331,433 shares of the biopharmaceuticDecember 16 at 3:49 AM | marketbeat.comWhat is Zacks Research's Estimate for AGIO Q1 Earnings?Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at Zacks Research reduced their Q1 2025 earnings per share estimates for shares of Agios Pharmaceuticals in a report issued on Wednesday, December 11th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmDecember 16 at 1:26 AM | marketbeat.comFmr LLC Raises Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Fmr LLC lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 283.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 45,393 shares of the biopharmaceutical company's stock after buying an additiDecember 15 at 3:22 AM | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Consensus Target Price from BrokeragesDecember 14, 2024 | americanbankingnews.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $5.03 Million Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 9.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional invesDecember 12, 2024 | marketbeat.comRoyal Bank of Canada Raises Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $57.00December 12, 2024 | americanbankingnews.comAgios Pharma’s Competitive Edge and Strong Efficacy Data Bolster Buy RatingDecember 11, 2024 | markets.businessinsider.comAgios Pharma’s Competitive Edge and Strong Efficacy Data Bolster Buy RatingDecember 11, 2024 | markets.businessinsider.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of "Moderate Buy" by BrokeragesAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has received a consensus rating of "Moderate Buy" from the eight brokerages that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and four have assigned a buyDecember 11, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Stock Price Expected to Rise, Scotiabank Analyst SaysDecember 11, 2024 | americanbankingnews.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Bought by Frazier Life Sciences Management L.P.Frazier Life Sciences Management L.P. raised its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 19.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,044,154 shares of the biopharmaDecember 10, 2024 | marketbeat.comAgios Pharmaceuticals price target raised to $75 from $53 at ScotiabankDecember 9, 2024 | markets.businessinsider.comAgios Crashes 19% After A Surprise Side Effect Hammered Its 'Very Safe' DrugDecember 9, 2024 | msn.comAgios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on MitapivatDecember 8, 2024 | markets.businessinsider.comAgios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on MitapivatDecember 8, 2024 | globenewswire.comBank of America Securities Gives a Buy Rating to Janux Therapeutics Inc (JANX)December 5, 2024 | markets.businessinsider.comAre Options Traders Betting on a Big Move in Agios (AGIO) Stock?December 5, 2024 | finance.yahoo.comParkman Healthcare Partners LLC Sells 161,317 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Parkman Healthcare Partners LLC lessened its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 36.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 285,099 shares of the biopharmaceutical company's stock after selling 161,317 sDecember 4, 2024 | marketbeat.comAgios Pharmaceuticals: A Long Overdue Follow UpDecember 4, 2024 | seekingalpha.comErste Asset Management GmbH Takes $97.20 Million Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Erste Asset Management GmbH acquired a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 2,184,900 shares of the biopharmaceutical company's stock, valued at appDecember 1, 2024 | marketbeat.comBellevue Group AG Sells 143,633 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Bellevue Group AG decreased its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 3.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,735,915 shares of the biopharmaceutical company'sDecember 1, 2024 | marketbeat.comCaligan Partners LP Raises Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Caligan Partners LP grew its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 12.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 579,717 shares of the biopharmaceutical company's stock after acquDecember 1, 2024 | marketbeat.comPDT Partners LLC Trims Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)PDT Partners LLC lowered its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 24.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,735 shares of the biopharmaceutical company'sDecember 1, 2024 | marketbeat.comVestal Point Capital LP Invests $33.77 Million in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Vestal Point Capital LP bought a new stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 760,000 shares of the biopharmaceutical company's stock, valued at approximateNovember 29, 2024 | marketbeat.comSummit Partners Public Asset Management LLC Takes Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Summit Partners Public Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchasNovember 29, 2024 | marketbeat.comIntech Investment Management LLC Buys Shares of 20,078 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Intech Investment Management LLC bought a new position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 20,078 shares of the biopharmaceutical company's stock, vNovember 29, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Lowers Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Connor Clark & Lunn Investment Management Ltd. reduced its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 40.3% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 22,273 shares of the biopharmaceutical company's stock afterNovember 28, 2024 | marketbeat.comFisher Asset Management LLC Has $38 Million Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Fisher Asset Management LLC raised its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 20.5% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 855,328 shares of the biopharmaceutical company's stock after purchasing an additionaNovember 27, 2024 | marketbeat.comLoomis Sayles & Co. L P Buys 163,503 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Loomis Sayles & Co. L P grew its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 36.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 612,366 shares of the biopharmaceutical company'sNovember 26, 2024 | marketbeat.comCholangiocarcinoma Treatment Market 2034: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsightNovember 22, 2024 | theglobeandmail.comAgios Pharmaceuticals, Inc.November 19, 2024 | cnn.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest UpdateAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the target of a large growth in short interest in October. As of October 31st, there was short interest totalling 4,340,000 shares, a growth of 5.6% from the October 15th total of 4,110,000 shares. Based on an average daily trading volume, of 524,700 shares, the short-interest ratio is presently 8.3 days. Currently, 7.9% of the company's stock are sold short.November 17, 2024 | marketbeat.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of "Moderate Buy" from AnalystsAgios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and four have assigned aNovember 16, 2024 | marketbeat.comLeerink Partners Sticks to Their Hold Rating for Agios Pharma (AGIO)November 13, 2024 | markets.businessinsider.comStockNews.com Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to HoldStockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday.November 9, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good NewsNovember 7, 2024 | finance.yahoo.comAgios Pharmaceuticals to present new data on mitapivat, tebapivatNovember 7, 2024 | markets.businessinsider.comAgios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and ExpositionNovember 5, 2024 | globenewswire.comAssenagon Asset Management S.A. Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)Assenagon Asset Management S.A. lowered its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 94.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,409 shares of the biophaNovember 4, 2024 | marketbeat.comBank of America Securities Reaffirms Their Buy Rating on Agios Pharma (AGIO)November 2, 2024 | markets.businessinsider.comAgios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagNovember 2, 2024 | finance.yahoo.comAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Call TranscriptNovember 2, 2024 | msn.comAgios Pharmaceuticals Reports Robust Q3 2024 ResultsNovember 2, 2024 | markets.businessinsider.comAgios Pharmaceuticals price target raised to $53 from $51 at ScotiabankNovember 2, 2024 | markets.businessinsider.comAgios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.comStockNews.com downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday.November 1, 2024 | marketbeat.comAgios Pharmaceuticals (NASDAQ:AGIO) Earns "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada reiterated an "outperform" rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a research report on Friday.November 1, 2024 | marketbeat.comScotiabank Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) StockScotiabank lifted their price target on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a "sector outperform" rating in a report on Friday.November 1, 2024 | marketbeat.com Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Musk threatens Liberal’s fake “energy crisis” (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now AGIO Media Mentions By Week AGIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGIO News Sentiment▼0.340.69▲Average Medical News Sentiment AGIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGIO Articles This Week▼145▲AGIO Articles Average Week Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Intra-Cellular Therapies News Roivant Sciences News Ascendis Pharma A/S News Revolution Medicines News Lantheus News Nuvalent News Legend Biotech News Blueprint Medicines News Elanco Animal Health News Cytokinetics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AGIO) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
